Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTUITION: aflibercept for idiopathic choroidal neovascularization in young adults
2013-005081-19Phase 2Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in Subretinal neovascularization, sponsored by Hospices Civils de Lyon. Primary endpoint: Change in BCVA at 52 weeks. Started Jun 2015; status: active.
02
Drugs
aflibercept
03
Conditions
Subretinal neovascularization
Beyond the preview
Go deeper on 2013-005081-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005081-19.